Femasys appoints Kelley Nicholas as chief commercial officer

ATLANTA - Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on women’s health products with a market capitalization of $29.6 million, announced Tuesday the appointment of Kelley Nicholas as Chief Commercial Officer. According to InvestingPro data, the company’s stock is currently trading near its Fair Value, despite showing significant volatility with a beta of -2.61.

Nicholas will lead the execution of Femasys’ commercial strategy to drive revenue growth across its portfolio, with emphasis on expanding in the U.S. infertility market and building international partnerships. The appointment comes as the company has demonstrated strong revenue growth of 62% over the last twelve months, though InvestingPro analysis indicates the company is quickly burning through cash.

With over 25 years of industry experience, Nicholas previously served as Head of Sales at NeuroPace, where she accelerated revenue and improved stock performance. She also worked as Global Vice President of Marketing at Hologic and held leadership positions at Medtronic, Baxter, Intuitive Surgical, and Covidien.

"Kelley brings a proven track record of driving substantial revenue growth and creating shareholder value," said Kathy Lee-Sepsick, CEO and Founder of Femasys, according to the company’s press release.

As part of her employment agreement, Nicholas will receive an inducement option to purchase 100,000 shares of Femasys common stock, vesting over four years.

Femasys manufactures and markets several women’s health products, including FemaSeed Intratubal Insemination for infertility treatment and FemVue for fallopian tube assessment. The company is also developing FemBloc, a non-surgical permanent birth control alternative that expects full regulatory approval in Europe by mid-2025.

The company’s products are designed to provide accessible, in-office therapeutic and diagnostic solutions for women’s health needs. According to the company, published clinical trial data shows FemaSeed is over twice as effective as traditional intrauterine insemination for low male sperm count. While maintaining a healthy gross profit margin of 66%, analysts tracking the stock have set price targets ranging from $3 to $12, suggesting significant potential upside. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial metrics to make informed investment decisions.

In other recent news, Femasys Inc. has announced the pricing of its latest public stock offering and concurrent private placement, aiming to raise approximately $4.5 million. This move is intended to support the expansion of commercial efforts and product development. The public offering consists of 3.6 million shares priced at $0.85 each, while the private placement involves 1,686,275 shares, with some directors and officers purchasing at $1.02 per share. Meanwhile, Femasys received a notice from Nasdaq, indicating that the company does not meet the minimum market value requirement for continued listing, giving it until November 17, 2025, to regain compliance.

Analysts have adjusted their outlooks on Femasys, with Jones Trading reducing its price target to $6.00 from $10.00, though maintaining a Buy rating. This adjustment considers Femasys’ first-quarter earnings report and anticipates a CE mark approval for FemBloc, a key product, by mid-2025. H.C. Wainwright also revised its price target for Femasys to $12.00 from $15.00, following a first-quarter sales report of $0.34 million, which was significantly below expectations. Despite the lower sales, U.S. revenues increased by 78% quarter-over-quarter, and recent partnerships are expected to boost sales later in the year. Both firms remain optimistic, maintaining Buy ratings on the stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.